Arrowhead Pharmaceuticals (ARWR) Given a $2.00 Price Target at Cantor Fitzgerald
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has been given a $2.00 price objective by investment analysts at Cantor Fitzgerald in a research note issued on Tuesday. The firm currently has a “hold” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential downside of 43.66% from the company’s current price.
A number of other equities research analysts also recently commented on the stock. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Piper Jaffray Companies upgraded shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target for the company in a report on Monday, November 27th. William Blair upgraded shares of Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, September 18th. Finally, Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $3.17.
Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at $3.55 on Tuesday. Arrowhead Pharmaceuticals has a twelve month low of $1.20 and a twelve month high of $4.54. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.84 and a current ratio of 3.84.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ING Groep NV acquired a new position in Arrowhead Pharmaceuticals during the third quarter valued at approximately $3,500,000. Geode Capital Management LLC lifted its position in Arrowhead Pharmaceuticals by 3.4% during the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock valued at $1,226,000 after buying an additional 21,654 shares in the last quarter. Allianz Asset Management GmbH acquired a new position in Arrowhead Pharmaceuticals during the third quarter valued at approximately $1,958,000. LMR Partners LLP acquired a new position in Arrowhead Pharmaceuticals during the second quarter valued at approximately $467,000. Finally, Schwab Charles Investment Management Inc. lifted its position in Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock valued at $742,000 after buying an additional 16,103 shares in the last quarter. 20.20% of the stock is currently owned by institutional investors and hedge funds.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.